Lichtinger Pedro Insider Trades

Insider Trading History

Track insider trading activity for Lichtinger Pedro. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals NRBO
Director
Holding Value $177k 74,833 shares
Last Trade
Jul 24, 2019 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$270k 15,000 shares
$18.00
$2.36
NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals NRBO
Director
Holding Value $25.5k 10,800 shares
Last Trade
Jan 29, 2018 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.82M 10,800 shares
$261.00
$2.36
NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals NRBO
Director
Holding Value $141k 59,833 shares
Last Trade
Mar 10, 2017 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$4.24M 18,479 shares
$229.25
$2.36
NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals NRBO
Director
Holding Value $116k 49,274 shares
Last Trade
Aug 10, 2016 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$2.34M 10,000 shares
$233.50
$2.36
NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals NRBO
Director
Holding Value $92.7k 39,274 shares
Last Trade
Aug 10, 2016 Purchase (Conversion)Shares acquired or disposed through conversion of a derivative or other security.
$9.17M 39,274 shares
$233.50
$2.36
NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals NRBO
Director
Holding Value $0 0 shares
Last Trade
Aug 04, 2016 Sale
No data
No data
$2.36
NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals NRBO
Director
Holding Value $142k 60,000 shares
Last Trade
Aug 04, 2016 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
No data
No data
$2.36
Eterna Therapeutics
Eterna Therapeutics ERNA
Director
Holding Value $160k 20,000 shares
Last Trade
Jul 01, 2014 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$306M 20,000 shares
$15,300.00
$8.01
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
Director
Holding Value $24k 20,000 shares
Last Trade
Jul 01, 2014 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$53.7k 20,000 shares
$2.69
$1.20
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
Director
Holding Value $24k 20,000 shares
Last Trade
Jul 01, 2013 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$71.4k 20,000 shares
$3.57
$1.20
Eterna Therapeutics
Eterna Therapeutics ERNA
Director
Holding Value $160k 20,000 shares
Last Trade
Jul 01, 2013 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$240M 20,000 shares
$12,000.00
$8.01
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
Director
Holding Value $152k 126,250 shares
Last Trade
Jun 04, 2013 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$548k 150,000 shares
$3.65
$1.20
Eterna Therapeutics
Eterna Therapeutics ERNA
Director
Holding Value $1.01M 126,250 shares
Last Trade
Jun 04, 2013 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$1.3B 120,000 shares
$10,800.00
$8.01
Eterna Therapeutics
Eterna Therapeutics ERNA
Director
Holding Value $240k 30,000 shares
Last Trade
Jun 04, 2013 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$324M 30,000 shares
$10,800.00
$8.01
Eterna Therapeutics
Eterna Therapeutics ERNA
Director
Holding Value $160k 20,000 shares
Last Trade
Jul 01, 2012 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$78M 20,000 shares
$3,900.00
$8.01
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
Director
Holding Value $24k 20,000 shares
Last Trade
Jul 01, 2012 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$79.5k 20,000 shares
$3.97
$1.20
Eterna Therapeutics
Eterna Therapeutics ERNA
Director
Holding Value $50.1k 6,250 shares
Last Trade
Apr 11, 2012 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$41.3M 6,250 shares
$6,600.00
$8.01
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
Director
Holding Value $7.5k 6,250 shares
Last Trade
Apr 11, 2012 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$24.9k 6,250 shares
$3.98
$1.20
Eterna Therapeutics
Eterna Therapeutics ERNA
Director
Holding Value $160k 20,000 shares
Last Trade
Jul 01, 2011 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$258M 20,000 shares
$12,900.00
$8.01
Lineage Cell Therapeutics
Lineage Cell Therapeutics LCTX
Director
Holding Value $24k 20,000 shares
Last Trade
Jul 01, 2011 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$103k 20,000 shares
$5.13
$1.20

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up